Anavo (anavotx.com): no confident changes recorded yet; website history since November 2026. Homepage last checked 12 November 2026.
First recorded website
Observed 12 November 2026
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
UNLOCKING THE PHOSPHATASE TARGET CLASS
UNLOCKING THE PHOSPHATASE TARGET CLASS: Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.
Homepage
Funding statements on the website
Siegal Dr Andrew Mortlock Our Investors Anavo has raised €28 million to date from a group of blue-chip international investors.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
Recorded changes
Newest observations first. Each interval bounds when the website changed; it is not an exact event date.
No changes recorded yet. Missing observations do not mean the company has not changed.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
Seen November 2026 · 1 capture · latest observed messagingUNLOCKING THE PHOSPHATASE TARGET CLASS
UNLOCKING THE PHOSPHATASE TARGET CLASS: Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.